Document Classification

Section Type: RESULTS

Text: After the treatment, the rate of changes of ovarian mass volume (among them, at 12 weeks after the first injection, the median was -55. 83 % in the test group, -68. 22 % in the control group, P = 0. 336), the distinct improvement rate of symptom scores and pelvic signs during non-menstrual days [among them, at 12 weeks after the first injection, the rate of lower abdomen pain was 47. 5 % (48/101) in the test group, 44. 0 % (44/100) in the control group, P = 0. 881], the hormone (E2, FSH, LH) levels [among them, at 12 weeks after the first injection, the serum level of E2, was (3338) pmol/L in the test group, (3840) pmol/L in the control group, P = 0. 414 ; the serum level of FSH, was (5. 12. 8) U/L in the test group, (5. 32. 3) U/L in the control group, P = 0. 666 ; the serum level of LH, was (0. 60. 8) U/L in the test group, (0. 60. 9) U/L in the control group, P = 0. 907], had no statistically significant difference between the two groups (all P > 0. 05).